Analyst Raises Price Target for Revolution Medicines Remains Bullish
As of January 16, 2024, Raymond James analyst Laura Prendergast remains bullish on Revolution Medicines (NASDAQ:RVMD), maintaining an "Outperform" rating. ...
Tag: RVMD
Don't Miss It
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
